Introduction: Recurrent central venous restenosis is problematic in patients with ipsilateral arteriovenous fistula. We report our experience using a drug-eluting stent for the treatment of recurrent central vein restenosis. Case report: A 60-year-old man consulted our hospital because of recurrent swelling of his left upper limb with radial-cephalic arteriovenous fistula that originated in the distal forearm. More than 3 years prior, two bare-metal stents were placed for the obstructed lesions in the left subclavian and brachiocephalic venous lesions, and repeated balloon angioplasty for recurrent in-stent stenosis was performed approximately every 3 months. Angiography with iodinated contrast agents revealed an approximately 3-cm-long restenosis at the distal part of the bare-metal stents. One drugeluting stent (Zilver PTX Drug-Eluting Peripheral Stent; Cook Medical, Bloomington, IN, USA) was deployed at the narrowing lesion, followed by balloon angioplasty. The stenotic lesion was successfully and safely dilated. The patient consulted our hospital 5.5 months after drug-eluting stent placement because of restenosis at the distal part of the drugeluting stent, but only in a shorter segment than before. Freedom from clinically driven target-lesion revascularization (TLR) extended from 3.1 to 5.5 months after drug-eluting stent placement. Although additional implantation of the second drug-eluting stent was required 14.6 months after the first drug-eluting stent placement, freedom from TLR before/after the second drug-eluting stent placement extended from 4.4 months to more than 8.6 months. Conclusion: Drug-eluting stent placement is an effective strategy for recurrent central venous stenosis in patients with ipsilateral arteriovenous fistula. To our knowledge, this is the first report of drug-eluting stent placement for recurrent venous stenosis in a patient undergoing hemodialysis.
Introduction
Central venous stenosis of the ipsilateral side of an arteriovenous fistula (AVF) is a serious problem for patients undergoing maintenance hemodialysis because the central vein is the closest vein to the heart. Guidelines recommend percutaneous intervention to treat central venous obstruction. 1, 2 Moreover, stent placement should be considered when acute elastic recoil of the vein after angioplasty or stenosis recurs within a 3-month period. 1 Bare-metal stents (BMSs) for the treatment of central venous stenosis and obstruction have been reported to have 1-year primary patency rates ranging from 14.3% to 77.1%. [3] [4] [5] [6] [7] However, the problem with in-stent stenosis has not been resolved. Therefore, the purpose of this study was to report our experience using a drug-eluting stent (DES) for the treatment of recurrent central venous restenosis.
Materials and methods
The Zilver PTX Drug-Eluting Peripheral Stent (Cook Medical, Bloomington, IN, USA) is a self-expanding nitinol stent with a polymer-free paclitaxel coating designed to deliver paclitaxel locally to the vessel wall in order to inhibit neointimal hyperplasia and reduce restenosis. According to porcine data, stents delivered approximately 95% of the total paclitaxel within 24 h after deployment. 8 Despite rapid delivery from the stent, paclitaxel levels in the vessel wall were sustained at approximately 20% of the peak level for 14 days and remained detectable for 56 days. Within 3 months, vessels with paclitaxel-coated BMSs showed comparable and complete healing. 8 The ethics committee and Institutional Review Board at Tsuchiya General Hospital approved this study (E160926-2).
Case report
A 60-year-old man consulted our hospital because of recurrent swelling of his left upper limb with radialcephalic AVF that originated in the distal forearm. His AVF originally occurred 7 years and 2 months prior to the consultation. He had right hemiplegia because of cerebral hemorrhage, and his right elbow was contracted.
More than 3 years prior, two BMSs were placed for the obstructed lesions in the left subclavian and brachiocephalic venous lesions, and repeated balloon angioplasty for recurrent in-stent restenosis was performed approximately every 3 months. Furthermore, the latest balloon angioplasty was performed 3.1 months before the consultation (Table 1 ). Due to continued recurrence of in-stent restenosis, we decided to use a DES. Angiography with iodinated contrast agents revealed an approximately 3-cm-long restenosis at the distal part of the BMS, and multiple collateral veins were identified around his shoulder (Figure 1 ). Balloon angioplasty was performed using a conventional balloon catheter (10 mm × 4 cm). One DES (8 mm × 4 cm; Zilver PTX) was carefully deployed at the in-stent restenosis to keep the entry of the cephalic arch open, followed by additional dilation using a conventional balloon catheter (8 mm × 8 cm). Then, the cephalic arch stenosis was dilated using the same balloon catheter from the cephalic vein. Good outflow through the stented segment and cephalic arch with only partial filling of the collateral veins were observed ( Figure 2 ). Aspirin was administrated after DES placement and was continued indefinitely.
The patient revisited our hospital 5.5 months after DES placement because of recurrent swelling of his left upper limb. Angiography revealed restenosis at the distal part of the DES, but only in a shorter segment than before (Figure 3(a) ). The stenotic lesion was successfully dilated using a conventional balloon catheter (8 mm × 4 cm; Figure 3 (b)). Freedom from clinically driven target-lesion revascularization (TLR) 
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extended from 3.1 to 5.5 months after DES placement. At this time, the cephalic arch, which was obstructed for 6 cm of its length, was also successfully dilated.
During another visit 10.4 months after DES placement, a Peripheral Cutting Balloon (5 mm × 2 cm; Boston Scientific Japan, Tokyo, Japan) was adopted. Unfortunately, at 14.6 months after DES placement, he visited our hospital again because of recurrence of left upper limb swelling. Digital subtraction angiography revealed restenosis of 1 cm in length at the distal part of the DES (Figure 4(a) ). A conventional balloon (7 mm × 4 cm) was adopted. As residual narrowing was recognized, one DES (Zilver PTX; 8 mm × 8 cm) was deployed from the subclavian vein to the axillary vein to deter the outflow of the cephalic arch (Figure 4(b) ). Although additional implantation of a second DES was required 14.6 months after the first DES placement, freedom from TLR extended from 4.4 months to more than 8.6 months. Recent interventions for central venous stenosis are summarized in Table 1 .
Discussion
We adopted a DES for treatment of a recurrent central instent restenosis. The restenosis at the distal margin of the DES was in a shorter segment than before. Freedom from clinically driven TLR extended from 3.1 to 5.5 months after DES placement. In addition, after the second DES deployment for a long segment from the axillary vein to the subclavian vein, freedom from clinically driven TLR was longer than 8.6 months.
In our case, two pathways were available-from the brachial vein to the axillary vein and from the cephalic vein to the cephalic arch. As the anastomosis was in the distal forearm, vascular access flow dispersed to both the brachial vein and the cephalic vein at the elbow. We initially thought that it would be better to maintain both the axillary and the cephalic routes. In addition, the first DES was deployed on the proximal side of the cephalic arch. However, because of recurrence at the distal margin of the DES, the second DES was necessary. Therefore, we believe that it would be better to initially deploy the long DES from the subclavian vein to the axillary vein, beyond the junction of the cephalic arch.
According to the ZILVER-PTX single-arm study for femoropopliteal in-stent restenosis, freedom from TLR was 96.2% at 6 months, 81.0% at 1 year, and 60.8% at 2 years. 9 This stent has some advantages. First, because it is a self-expanding stent, it retains its internal diameter. Second, this stent delivers low-dose paclitaxel to inhibit smooth muscle proliferation without inhibiting endothelial cell proliferation. 10 As the data of these studies were from arteries, they are not directly applicable to veins. However, our data imply the possibility that the Zilver PTX DES prolongs the freedom from TLR for in-stent restenosis of AVF.
Other approaches for resolving recurrent central venous stenosis have been reported. For example, Massmann et al. 11 compared paclitaxel-coated balloon angioplasty (PCBA) to balloon angioplasty for symptomatic central venous restenosis in patients with hemodialysis fistulas. The median freedom from TLR after balloon angioplasty was 5 months. Conversely, after PCBA, more than 50% of patients were event-free during the observation period (mean freedom from TLR: 10 months). Furthermore, median restenosis intervals were longer following PCBA than following balloon angioplasty (9 vs 4 months; p = 0.023). Our data from the second DES placement were comparable with those reported by Massmann et al. Another prospective randomized study of an expanded polytetrafluoroethylene stent graft in comparison with balloon angioplasty for in-stent restenosis in arteriovenous grafts and fistulas was published. 12 When stratified by location in the central veins, the treatment area primary patency (TAPP) at 6 months was 63.4% for the stent-graft group and 4.3% for the balloon angioplasty group (p < 0.001). Since TAPP of our data from the second DES placement was longer than 8.6 months, our data were also comparable with those for the stent graft.
This study had some limitations. First, our study was a retrospective case report. To clarify the effectiveness of DES for central venous in-stent restenosis, a prospective study would be required. Second, in this case, only aspirin therapy was administrated, although dual antiplatelet therapy is usually administered to patients receiving DES placement. Taking into consideration the history of cerebral hemorrhage, we chose a single antiplatelet therapy. Fortunately, thus far, no thrombosis has occurred within the stents.
Conclusion
DES placement is an effective strategy for recurrent central venous stenosis in patients with ipsilateral AVF. To our knowledge, this is the first report of DES placement for recurrent venous stenosis in a patient undergoing hemodialysis.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. 
